BioSpace News Archive

Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that Dr Megan Baldwin, the Company’s Chief Executive Officer, will present at Oppenheimer’s 32nd Annual Healthcare Conference, being held virtually from March 15-17, 2022.

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, announced that senior management will present at the following upcoming virtual investor conferences.

ObsEva SA, a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, reported financial results for the full year ended December 31, 2021 and provided a business update.

Amicus Therapeutics, announced one oral presentation and two posters highlighting its development program for Pompe disease will be included at the 2022 MDA Clinical & Scientific Conference, being held March 13-16, 2022 in Nashville, TN and virtually.

Foghorn Therapeutics Inc. provided a corporate update including the Company’s 2021 key achievements and 2022 strategic priorities in conjunction with its 10-K filing for the year ended December 31, 2021.

Umbra Applied Technologies Group, Inc’s, announced that its subsidiary, Ossifix Orthopedics has entered into full scale production of its Javelin fixation pin.

Genocea Biosciences, Inc., a biopharmaceutical company developing next-generation neoantigen immunotherapies, provided a business update for the fourth quarter ended December 31, 2021.

Cipher Pharmaceuticals Inc. announced that it has entered into a second amended and restated distribution and supply agreement with Sun Pharmaceutical Industries, Inc., a wholly owned subsidiary company of Sun Pharmaceutical Industries Limited, India.

Regen BioPharma, Inc. announced a program to accelerate the clinical development of its NR2F6 therapies.

Evogene Ltd., a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, announced its financial results for the fourth quarter and full year of 2021, ended December 31, 2021.